文献速递造血干细胞移植与细胞治疗白血病

TCRαβ/CD19细胞去除HLA单倍体相合移植治疗儿童急性白血病:更新最终分析

TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
PubMed 文献 · Blood · 2024-01-01

报告213例儿童急性白血病接受TCRαβ/CD19细胞去除HLA单倍体相合造血干细胞移植的更新分析,中位随访47.6个月,5年非复发死亡率5.2%、复发率22.7%,预计10年总生存75.4%、无病生存71.6%,急慢性GVHD发生率低。多因素分析显示预处理含全身照射、移植时疾病状态和移植前微小残留病水平与无病生存独立相关。

要点

  • 5年非复发死亡率5.2%,复发率22.7%,预计10年总生存75.4%、无病生存71.6%。
  • II-IV级急性GVHD累积发生率14.7%,慢性GVHD 8.1%。
  • 预处理含全身照射与更好无病生存独立相关(HR 0.5)。

核心结论

  • 该更新分析证实TCRαβ/CD19细胞去除HLA单倍体相合移植在儿童急性白血病中预后良好,并识别出治疗失败风险较高的患者,作者认为这些患者需要个体化策略以降低复发风险。

研究设计与样本

  • I-II期临床试验(NCT01810120)的更新最终分析,纳入213例接受TCRαβ/CD19细胞去除HLA单倍体相合造血干细胞移植的儿童急性白血病患者,存活患者中位随访47.6个月。

主要发现

  • 5年非复发死亡累积发生率为5.2%(95%CI 2.8%-8.8%),复发累积发生率为22.7%(95%CI 16.9%-29.2%)。
  • 预计10年总生存率为75.4%(95%CI 68.6%-80.9%),无病生存率为71.6%(95%CI 64.4%-77.6%)。
  • II-IV级急性GVHD累积发生率为14.7%,慢性GVHD累积发生率为8.1%。
  • 多因素分析中,预处理含全身照射与无病生存改善独立相关(HR 0.5;95%CI 0.26-0.98;P=0.04)。
  • 移植时疾病状态为完全缓解≥3次对比完全缓解1/2次(HR 2.23;95%CI 1.20-4.16;P=0.01)及移植前微小残留病高水平(HR 2.09;95%CI 1.01-4.33;P=0.04)与无病生存独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TCRαβ/CD19 cell depletion is a promising graft manipulation technique frequently used in the context of human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (HSCT). We previously reported the results of a phase I-II clinical trial (NCT01810120) to assess the safety and the efficacy of this type of exvivo T-cell depletion in 80 children with acute leukemia, showing promising survival outcomes. We now report an updated analysis on a cohort of 213 children with a longer follow-up (median, 47.6 months for surviving patients). With a 5-year cumulative incidence of nonrelapse mortality of 5.2% (95% confidence interval [CI], 2.8%-8.8%) and a cumulative incidence of relapse of 22.7% (95% CI, 16.9%-29.2%), projected 10-year overall and disease-free survival (DFS) were 75.4% (95% CI, 68.6%-80.9%) and 71.6% (95% CI, 64.4%-77.6%), respectively. Cumulative incidence of both grade II-IV acute and chronic graft-versus-host disease were low (14.7% and 8.1%, respectively). In a multivariable analysis for DFS including type of disease, use of total body irradiation in the conditioning regimen (hazard ratio [HR], 0.5; 95% CI, 0.26-0.98; P = .04), disease status at HSCT (complete remission [CR] ≥3 vs CR 1/2; HR, 2.23; 95% CI, 1.20-4.16; P = .01), and high levels of pre-HSCT minimal residual disease (HR, 2.09; 95% CI, 1.01-4.33; P = .04) were independently associated with outcome. In summary, besides confirming the good outcome results already reported (which are almost superimposable on those of transplant from HLA-matched donors), this clinical update allows the identification of patients at higher risk of treatment failure for whom personalized approaches, aimed at reducing the risk of relapse, are warranted.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Merli P, Algeri M, Galaverna F, et al. TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024. PMID: 37738655. doi:10.1182/blood.2023021336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。